Plus Therapeutics Announces Reverse Stock Split to Meet Nasdaq Listing Requirements
Summary
Plus Therapeutics announced a reverse stock split aimed at increasing its per-share trading price to comply with Nasdaq's minimum bid price requirement. This action directly addresses the Nasdaq delisting risk highlighted in the company's 10-K filing on March 12, 2026. For a micro-cap company with a stock price of $0.18, a reverse split is a significant corporate event, often signaling underlying financial challenges and a last-resort effort to maintain exchange listing. While it prevents immediate delisting, it does not fundamentally alter the company's valuation or operational performance, and can sometimes lead to further stock price volatility post-split. Traders will be watching for the specific ratio of the split and its impact on market sentiment.
At the time of this announcement, PSTV was trading at $0.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $36.8M. The 52-week trading range was $0.16 to $1.36. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.